Michaud K, Solomon D, Oermann E, Kim J, Zhong W, Prados M, Ozawa T, James C, Waldman T Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.

Mogi A, Kuwano H TP53 mutations in nonsmall cell lung cancer.

Molina-Vila M, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto A, Cardona A, Vergnenègre A, Majem M, Mas[illegible]B, Morán T, Carcereny E, Viteri S, Rosell R Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.

O'Leary B, Finn R, Turner N Treating cancer with selective CDK4/6 inhibitors.

Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel C, Hainaut P Recent advances in p53 research: an interdisciplinary perspective.

Pirollo K, Nemunaitis J, Leung P, Nunan R, Adams J, Chang E Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 G[illegible]ced in Combination [illegible]ocetaxel: A Phase 1b Study.

Saito H, Ando S, Morishita N, Lee K, Dator D, Dy D, Shigemura K, Adhim Z, Nibu K, Fujisawa M, Shirakawa T A combined lymphokine-activated killer (LAK[illegible]mmunotherapy a[illegible]enovirus-p53 gene therapy for head and neck squamous cell carcinoma.

Santibáñez-Koref M, Birch J, Hartley A, Jones P, Craft A, Eden T, Crowther D, Kelsey A, Harris M p53 germline mutations in Li-Fraumeni syndrome.

Schuler P, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield L, Whiteside T, Ferris R Phase I dendritic cell p53 peptide vaccine for[illegible]d neck cancer.

Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo K, Rait A, Chang E Phase I study of a systemically delivered p53 nanoparticle in a[illegible]d solid tumo[illegible]

Spigel DR, Dakhil S, Beck JT Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung canc[illegible] (NSCLC): Lead-in cohort results

Srivastava S, Zou Z, Pirollo K, Blattner W, Chang E Germ-line transmission of a mutated p53 gene in a cancer-prone family with L[illegible]eni syndrome.

Taylor-Harding B, Aspuria P, Agadjanian H, Cheon D, Mizuno T, Greenberg D, Allen J, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S[illegible]C, Karlan B, Wiedemeyer W Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Tekpli X, Landvik N, Skaug V, Gulsvik A, Haugen A, Zienolddiny S Functional effect of polymorphisms in 15q25 locu[illegible]A5 mRNA, bu[illegible] adducts and TP53 m[illegible]ns.

Tentler J, Ionkina A, Tan A, Newton T, Pitts T, Glogowska M, Kabos P, Sartorius C, Sullivan K, Espinosa J, Ecl[illegible], Diame[illegible]53 Family Me[illegible]Regulate Ph[illegible]ic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Vermeij R, Leffers N, van der Burg S, Melief C, Daemen T, Nijman H Immunological and clinical effects o[illegible]lines targeting p53-c[illegible]xpressing malign[illegible]

Viatour P, Ehmer U, Saddic L, Dorrell C, Andersen J, Lin C, Zmoos A, Mazur P, Schaffer B, Osterm[illegible]Vogel H, Sylvester K, T[illegible]eirsson S, Grompe M, S[illegible]ge J Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway.

Vignot S, Frampton G, Soria J, Yelensky R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross J, C[illegible]André F, S[illegible]is P, Lazar V, Miller V, Brambilla E Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with no[illegible]cell lun[illegible]er.

Vilgelm A, Pawlikowski J, Liu Y, Hawkins O, Davis T, Smith J, Weller K, Horton L, McC[illegible]ers G, Turner D[illegible], Stewart C, Sosman J, Kelley M, Ecsedy J, Johnston J, Richmond A Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and[illegible]earance of tum[illegible]

Wang Y, Lin R, Tan Y, Chen J, Chen C, Wang Y Wild-type p53 overexpression and its co[illegible]MDM2 and p14[illegible]erations: an alternative pathway to non-small-cell lung cancer.

Wiedemeyer W, Dunn I, Quayle S, Zhang J, Chheda M, Dunn G, Zhuang L, Rosenbluh J, C[illegible]S, Xi[illegible]Shapiro G, Hahn[illegible]n L Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Xiao B, Spencer J, Clements A, Ali-Khan N, Mittnacht S, Broceño C, Burghammer M, Perrakis[illegible]armorstet[illegible]Gamblin S Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation.

Young R, Waldeck K, Martin C, Foo J, Cameron D, Kirby L, De[illegible]ullinane C, Liu W, [illegible]S, Dutton-R[illegible]K, Hayward N, Jene N, Dobrovic A, Pearson R, Christensen J, Randolph S, McArthur G, Sheppard K Loss of CDKN2A expression is a frequent event[illegible]melanoma and[illegible]elates with se[illegible]tivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Zagorski W, Knudsen E, Reed M Retinoblastoma deficiency increas[illegible]mosensi[illegible]g cano[illegible]

Zöchbauer-Müller S, Fong K, Virmani A, Geradts J, Gazdar A, Minna J A[illegible]promoter me[illegible]ultiple genes in non-small cell lung cancers.

NCCN NCCN Guidelines® are referenced with permission from the NCCN C[illegible]ractice Guidelines [illegible]Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.1.2016, Breast Cancer V.1.2016, Central Nervous System Cancers V.1.2015[illegible]ic Cancer V.3.2015, Non-Sma[illegible]lung Cancer V.4.2016, Colon Cancer V.2.2016, Rectal Cancer V.1.2016, Melanoma V.2.2016, Neuroendocrine Tumors V.1.2015, Ovarian Cancer V.2.2015, Pan[illegible]carcinoma V.1.2016, Prosta[illegible]ncer V.2.2016, and Uterine Neoplasms V.2.2016. © 2016 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illu[illegible]on[illegible]y not be reproduced in a[illegible]m for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online[illegible]CCN.o[illegible]

Electronic Signature

Sample Doctor, M.D., Pathol[illegible]t - N[illegible]oGenomics Laboratories

The Technical Co[illegible]cessing, Analysis a[illegible]ional Component of this test was completed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA / 92656 / 866-776-5907 / CLIA #05D1021650[illegible]al Director(s): Lawrence Weis[illegible].
The perform[illegible] characteristics of this test have be[illegible]ermined by NeoGenomics Laboratories. This test has not been approved by the FDA. The FDA has determined such clearance or approval is not necessar[illegible]s laboratory is CLIA certified to perform[illegible]complexity clinical testing.
Images[illegible]may be included within this report are repr[illegible]tative of the patient but not all testing in its entirety and should not be used to render a result.

SAMPLE

© 2018 NeoGenomics Laboratories, Inc. All rights reserved. NeoGenomics Laboratories and the associated logo are trademarks of NeoGenomics Laboratories, Inc.